Pituitary growth hormone (GH) and insulinlike growth factor (IGF)-1 are anabolic hormones whose physiological roles are particularly important during development. The activity of the GH/IGF-1 axis is controlled by complex neuroendocrine systems including two hypothalamic neuropeptides, GH-releasing hormone (GHRH) and somatostatin (SRIF), and a gastrointestinal hormone, ghrelin. The neurotransmitter acetylcholine (ACh) is involved in tuning GH secretion, and its GH-stimulatory action has mainly been shown in adults but is not clearly documented during development. ACh, together with these hormones and their receptors, is expressed before birth, and somatotroph cells are already responsive to GHRH, SRIF, and ghrelin. We thus hypothesized that ACh could contribute to the modulation of the main components of the somatotropic axis during development. In this study, we generated a choline acetyltransferase knockout mouse line and showed that heterozygous mice display a transient deficit in ACh from embryonic day 18.5 to postnatal day 10, and they recover normal ACh levels from the second postnatal week. This developmental ACh deficiency had no major impact on weight gain and cardiorespiratory status of newborn mice. Using this mouse model, we found that endogenous ACh levels determined the concentrations of circulating GH and IGF-1 at embryonic and postnatal stages. In particular, serum GH level was correlated with brain ACh content. ACh also modulated the levels of GHRH and SRIF in the hypothalamus and ghrelin in the stomach, and it affected the levels of these hormones in the circulation. This study identifies ACh as a potential regulator of the somatotropic axis during the developmental period. (Endocrinology 159: 1844(Endocrinology 159: -1859(Endocrinology 159: , 2018 G rowth hormone (GH) is mainly produced by somatotroph cells within the anterior pituitary gland and, through its release into the blood flow, controls the production and the serum concentration of hepatic insulinlike growth factor (IGF)-1, a potent mitogen that circulates to target organs and induces a number of cellular responses. GH and IGF-1 are also synthesized at low levels in extrapituitary and extrahepatic tissues,
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Circulating GH regulated by a range of external stimuli and endogenous factors. The primary hormonal control of GH secretion occurs via the interplay between concentration is two hypothalamic neuropeptides, GHreleasing hormone (GHRH) and somatostatin (SRIF), and a gastrointestinal hormone, ghrelin (2) . The hypophysiotropic GHRH and SRIF neurons are mainly localized within the arcuate and the periventricular nuclei, respectively (16) . Both hormones are delivered through the portal system to pituitary somatotroph cells, where they act in concert to antagonistically regulate GH secretion by exerting stimulatory and inhibitory influences, respectively. SRIF neurons also provide inhibitory inputs on GHRH neurons (16) . In synergy with GHRH, ghrelin displays a potent GH-releasing activity (17) , either by acting directly on pituitary cells or through the stimulation of GHRH release by hypothalamic neurons (18) . The oxyntic glands in the stomach are the major source of circulating ghrelin (19) . This hormone is also synthesized in small amounts by other peripheral organs and at extremely low levels in the pituitary and the hypothalamus (19) . To maintain a normal GH/IGF-1 axis function, a homeostatic equilibrium between the stimulation and the inhibition of its activity is needed, which requires the tight regulation of the cells producing GHRH, SRIF, and ghrelin.
Among the multiple factors that modulate the secretion of these three hormones and of GH, the neurotransmitter acetylcholine (ACh) has been recognized as a prominent player. This was shown in humans and animal models by the pharmacological manipulation of cholinergic signaling (20) (21) (22) (23) and further highlighted by mutations in cholinergic receptor genes (24, 25) . However, all of these studies were essentially restricted to the adulthood, particularly the pharmacological approaches in humans, and little is currently known about the role of the cholinergic system on the regulation of the somatotropic axis during development.
The main components of the hypothalamic/somatotropic axis, that is, GH (26) , IGF-1 (26), GHRH (27) , SRIF (27) , stomach-derived ghrelin (28) , and their receptors (26, (29) (30) (31) (32) , are already expressed during the prenatal period in mammals. Furthermore, the developing somatotroph cells appear to possess the biochemical machinery required for effective GH response to GHRH, SRIF, and ghrelin (28, 33) . The components of the cholinergic system are also present in the brain during prenatal life, most of them before neuronal differentiation (34) . In the fetal stomach, cholinergic neurons are in place, cholinergic receptors are expressed in oxyntic glands, and the cholinergic innervation of the smooth muscle is already functional (35, 36) . Therefore, all the components required for cholinergic control of the GH/IGF-1 axis are present at early stages of life.
Here, using a mouse line bearing a mutation in the gene encoding choline acetyltransferase (ChAT), the AChsynthesizing enzyme, we tested the hypothesis that pituitary GH and its principal hypothalamic and peripheral mediators are under cholinergic control during development. We first generated this mouse model and showed that heterozygous mice display a transient ACh deficit specific for the embryonic and neonatal stages. Next, we examined the consequences of this ACh deficiency on the circulating levels of GH and IGF-1, from embryonic day (E)18.5, when cholinergic molecules are expressed and GH-secreting cells are functional in vivo, to postnatal day (P)21. We analyzed the impact of this deficit on GHRH, SRIF, and ghrelin concentrations in circulation and in their main tissues of origin during this developmental period.
Materials and Methods

Ethics
All experiments were performed in accordance with the European Union Guidelines for the Care and Use of Animals and were approved by the Veterinary Inspection Office in compliance with French legislation (agreement numbers B75-13-03, B75-13-04, and 2012-15/676-0096). They met recommendations of reduction, refinement, and replacement (known as the three Rs).
Animals and genotyping
We previously reported the generation of a Tri-lox mouse strain, in which both the eighth exon of the ChAT gene and a neomycin resistance selection cassette were floxed [ Fig. 1(a) ] (37). These mice were crossed to MeuCre40 transgenic mice (38) and the resulting mosaic males were mated to C57BL/6 mice. Polymerase chain reaction (PCR) analysis of the genome of 138 heterozygous mice, as described (37) , identified 14 ChAT +/2 mice harboring a mutant allele with an ;1.5 kb deletion containing both the eighth exon and the selection cassette [ Fig. 1(a) ]. These heterozygous mice were backcrossed for .10 generations to the C57BL/6 strain and then intercrossed to generate ChAT 2/2 mice. Litter sizes ranged from four to nine pups, as expected for the C57BL/6 strain, with both genotypes represented, thus allowing for littermate controls. Mice were housed two to four per cage by sex and litter regardless of the genotype in a specific pathogen-free facility, with food and water available ad libitum and a 12-hour light/dark schedule (lights on at 7:30 AM). Pregnant mice were euthanized by cervical dislocation and embryos were removed by cesarean delivery. All the embryos used in this study were at E18.5, with E0.5 defined as the morning of the day a vaginal plug was found after overnight mating. Embryos were immediately weighed and photographed on graph paper to estimate their size. Because of the kyphosis displayed by the homozygous embryos (see Results), the body length was not evaluated by the standard crown-rump length, but by measuring the maximum distance from the middle of the crown to the base of the tail all along the spine. Embryos and neonatal mice (until P7) were anesthetized by hypothermia before being euthanized for experiments. Pups from P10 to P21 were euthanized by cervical dislocation. All the ChAT +/2 mice analyzed at postnatal stage were obtained by mating wild-type (WT) females with heterozygous males. Mice were genotyped and embryos and newborns were sexed by PCR analysis of tail genomic DNA with the following set of primers: (1) genotype: primers P1, 5
0 -AGGTGCATGGTAGA-TGTGTG-3 0 (forward) and P3, 5 0 -TAG-TGGTCACAGCTACTCTC-3 0 (reverse) were used to assess the deletion of exon 8 (457-bp PCR product); primers P2, 5 0 -GGTTCTACAGGATCAATAAGG-3 0 (forward) and P3 (reverse, sequence above) were used to detect the WT allele (306-bp product), by which no PCR product was obtained for the mutant allele [ Fig. 1 (a) and 1(b)]; (2) sex: primers 5 0 -CACCTGCAC-GTTGCCCTT-3 0 (forward) and 5 0 -TGGA-TGGTGTGGCCAATG-3 0 (reverse) generated by 252-bp and 334-bp PCR products specific to the X and Y chromosomes, respectively. Both male and female embryos and pups were used in this study.
Alcian blue and Alizarin red staining E18.5 embryos were harvested, anesthetized on ice, peeled, eviscerated, fixed in 100% ethanol for at least 4 days, incubated in 100% acetone for 4 days, washed in tap water, stained in Alcian blue/Alizarin red solution (39) , and stored at room temperature in 80% glycerol.
Plethysmography
Vital functions (breathing variables, heart rate and activity) were measured simultaneously and noninvasively on unanesthetized and unrestrained pups, using whole-body flow plethysmograph as previously described (40) . Plethysmograph chambers were thermoregulated at 33°C and equipped with electrodes embedded in the floor to record heart rate. Movements were also detected on the basis of large disturbances in the respiratory signal (41) . Briefly, pups were randomly taken from the litter and, after 2 minutes of familiarization inside the chamber, testing was performed under basal condition (room air) and, to test respiratory reflexes by switching the airflow through the plethysmograph, in response to either hypercapnia (8% CO 2 plus 21% O 2 plus 71% N 2 ) or hypoxia (10% O 2 plus 90% N 2 ). Mice were exposed for 35 consecutive minutes to the following conditions: 10 minutes air; 5 minutes hypercapnia; 10 minutes air; 3 minutes hypoxia; 7 minutes air. Variables were continuously monitored and breathing parameters and heart rate were averaged, whereas movements were summed, during consecutive 30-second periods. Breath duration (in seconds), tidal volume (V T , mL/g), and minute ventilation (V E , calculated as V T /breath duration and expressed in mL/s/g) were determined on apnea-free and movement-free periods. Apneas were defined as ventilatory pauses longer than twice the duration of the preceding breath and determined as previously described (41) . To correct for mouse-to-mouse weight differences, V T and hence V E were individually normalized to the mouse body weight. Mice of both genotypes analyzed in this study displayed homogeneous weights [P5, 2.63 6 0.34 g (WT, n = 54) and 2.59 6 0.42 g (ChAT +/2 , n = 48); P15, 6.41 6 0.58 g (WT, n = 38) and 6.50 6 0.58 g (ChAT 2/2 , n = 32)]. Total apnea duration was calculated during successive 30-second periods. Heart rate (in beats per minute) was determined as described (40) . In each series of experiments, all the mice were tested on the same day in random order prior to genotyping.
ACh and hormone assays
ACh was measured by cationic exchange high-performance liquid chromatography combined with electrochemical detection as described in detail previously (42) . The specificity of the ACh peak was checked by using an analytical column packed with 40 U acetylcholinesterase (AChE). This application specifically eliminates the ACh peak, but the choline peak remains (42). Detection limit was 20 fmol of ACh per injection. Within-assay variability was 1.7% and between-assay variability was 4.8%.
Blood samples collected in cooled tubes were allowed to clot at 4°C for 30 minutes and then centrifuged at 1000 3 g for 10 minutes at 4°C. Serum was aliquoted and stored at 280°C until it was assayed for hormone content. Serum hormone concentrations were determined by radioimmunoassay for IGF-1 (DSL-2900, Diagnostic Systems Laboratories, Webster, TX; within-assay variability, 5.6%; between-assay variability, 9.1%) and enzyme-linked immunosorbent assay for GH (LS-F26595-1, LifeSpan Biosciences, Seattle, WA; within-assay variability, 1.5%; between-assay variability, 6.1%), GHRH (ABIN2642453, Antibodies Online; withinassay variability, 4.5%; between-assay variability, 13.4%), SRIF (ABIN367816, Antibodies Online; within-assay variability, 3.3%; between-assay variability, 11.1%), and total (i.e., acylated and deacylated) ghrelin (KT-364, Kamiya Biomedical, Seattle, WA; within-assay variability, 2.9%; betweenassay variability, 7.2%). To quantify hypothalamic levels of GHRH and SRIF, as well as stomach levels of ghrelin, tissue extracts were prepared by homogenization in the presence of sulfhydryl-activated toxin as described (43) . Hormone levels were measured using the same methodologies as for serum. All the assays were performed in triplicate by experimenters blinded to the genotypes.
Statistical analysis
For body weight measurements and ACh or hormone assays, variables were subjected to standard factorial analysis of variance (ANOVA) using GraphPad Prism software, with genotype as between-subject factor and age as within-subject factor for the postnatal analyses. Significant main effects and ageby-genotype interactions were further analyzed by pairwise comparisons of means using a post hoc Bonferroni test. The statistical relationships between ACh and hormone levels were evaluated using a Pearson correlation analysis from data obtained in WT and mutant mice. Physiological variables were subjected to repeated measure ANOVA with genotype as a between-subject factor, and statistical analyses were conducted using R software. Statistical significance was considered when a P value was ,0.05. Sex had no significant effect, except on GHRH levels in the hypothalamus, the differences in which were not related to the genotype (genotype-by-sex interactions not significant). The results presented in the figures were obtained by pooling the values collected from males and females. 
Results
ChAT-knockout embryos
ChAT-null mice were generated by deletion of the eighth exon of the ChAT gene [ Fig. 1(a) ], which introduces a frame shift and leads to the synthesis of a truncated and inactive protein. Mutant mice were born at the expected Mendelian frequency, and ChAT gene mutation had no impact on litter size. Whereas heterozygous embryos apparently displayed no overt malformation, ChAT 2/2 embryos developed to term with abnormalities and died at birth, most likely from respiratory insufficiency. They were visibly cyanotic, completely paralyzed because of the lack of neuromuscular transmission, and displayed morphological anomalies such as a kyphosis or a large abdominal perimeter [ Fig. 1(c) ]. This is consistent with the phenotype of two other mutant mouse models obtained by deletion of other exons in the ChAT gene (44, 45) . The average weight of ChAT-null mice did not differ from their WT counterparts, whereas their body length was slightly (8%) but significantly decreased as compared with WT and ChAT +/2 littermates [ Fig. 1(d) ].
We found that a highly dilated bladder filled with urine, which took up most of abdominal cavity, accounted, at least in part, for their large abdomen. Histological analysis of the rachis revealed a prominent skeletal malformation in homozygous embryos that consisted of the fusion of the joints of the vertebral articular processes [ Fig. 1(e) ]. This abnormality was observed at the cervical, thoracic, and lumbar levels and may explain their hunched posture.
ChAT +/2 mice: a model of cholinergic hypofunction specific for the embryonic period and early postnatal stage
ChAT mutant embryos presented ACh deficits in the brain and the intestine, which contains early differentiating ACh-producing cells of nonneuronal and neuronal origins and receives a cholinergic parasympathetic innervation easily detectable at early developmental stages (46) . Homozygous embryos lacked ACh and heterozygous embryos displayed ;50% to 60% lower levels of ACh relative to WT littermates [ Fig. 2(a) and 2(c) ]. We next investigated whether this deficit was maintained during postnatal development in ChAT +/2 mice. ACh levels were measured in ChAT +/2 pups and WT littermates from P2 to P21 in the brain and the intestine. Although the amount of brain ACh did not significantly change during this period in WT mice (P = 0.2556), it varied with age in ChAT +/2 pups (P , 0.0001): from P2 to P10, ACh content was significantly lower than in WT animals, then it abruptly increased to reach from P14 a level equivalent to that of WT mice [ Fig. 2(b) ]. A similar age-dependent variation pattern was found in the intestine, except that ACh recovered to normal levels by P21 in ChAT +/2 mice [ Fig. 2(d) ]. These results demonstrate that ChAT +/2 mice develop, from the embryonic stage to P10, with a deficit in endogenous ACh that is not restricted to the central nervous system.
ChAT
+/2 newborn mice display a normal physiological status
We next explored in detail the physiological status of the ChAT +/2 newborn mice. These mice displayed very similar body weights and body lengths to those of WT counterparts from birth to P21 [ Fig. 3(a) ], without any significant effect of sex on either variables [Supplemental Fig. 1(a) and 1(b) ; Supplemental Tables 4 and 5] . Body weights remained similar in adult WT and ChAT +/2 mice, at least until 6 months of age [Supplemental Fig. 1(c) Fig. 3(c) ]. In response to either hypercapnia or hypoxia, ChAT +/2 mice increased ventilation to the same degree as WT mice. Apnea duration, which reflects the respiratory instability characteristic of newborns, varied similarly in WT and ChAT +/2 littermates, regardless of the air chamber composition [ Fig. 3(d) ]. ChAT +/2 pups thus appeared to exhibit normal respiratory function and chemosensitivity to both carbon dioxide and oxygen. Furthermore, no significant differences were detected in heart rate between WT and ChAT +/2 mice [ Fig. 3(e) ]. In both groups, heart rate decreased with CO 2 breathing and increased in hypoxic condition. The heart rate control is thus normal during development in ChAT +/2 mice. Finally, there were no significant genotyperelated differences in the behavioral response to hypercapnic or hypoxic challenges, as reflected by the duration of gross body movements [ Fig. 3(f) ]. The arousal response to these challenges is an important defensive reflex, and abnormal development of this reflex may impair responsiveness to hypoxia. Thus in early postnatal life, ChAT +/2 pups exhibit normal cardiorespiratory function and behavioral responses to chemical challenges, despite their impaired cholinergic tone. These mice thus turn out to be particularly appropriate to investigate in vivo the effects of the cholinergic deficit specifically on the regulation of the somatotropic GH/ IGF-1 axis during development.
ACh affects serum GH and IGF-1 levels in embryos and newborn mice
Whether the developmental ACh deficit displayed by ChAT +/2 mice affects the GH/IGF-1 axis was assessed by measuring GH and IGF-1 concentrations in the serum collected from E18.5 to P21 mice. At E18.5, the levels of serum GH were reduced by 25% and 56% in heterozygous and in homozygous embryos, respectively, as compared with WT littermates [ Fig. 4(a) ]. After birth, the temporal pattern of circulating GH almost paralleled that of brain ACh: in WT mice, serum GH concentration remained constant from P2 to P21 (P = 0.2171), whereas in ChAT +/2 mice, it was significantly lower until P10 and reached WT levels at P14 and thereafter [ Fig. 4(b) ]. There was a strong positive correlation between circulating GH and brain ACh levels [ Fig. 4(c) ]. Analyses within each age group at E18.5, P2, and P10 confirmed this correlation, showing that it was not due to a confounding effect of age [Supplemental Fig. 2 (a); Supplemental Table 7 ]. Moreover, circulating IGF-1 was dramatically reduced in E18.5 mutant mice [51% and 73% decrease in ChAT +/2 and ChAT 2/2 mice, respectively, relative to WT embryos; Fig. 4(d) ]. Postnatally, the deficit in serum IGF-1 persisted in heterozygous newborns until P10, the age at which IGF-1 concentration became equivalent to that of WT animals [ Fig. 4(e) ]. Note that the variation profiles of serum IGF-1 differed from those of GH and ACh, in that it decreased in WT neonates in an age-dependent manner. This decline of serum IGF-1 in the immediate postnatal period is consistent with previous data obtained in the rat (47) . Altogether, these results provide evidence that, during the developmental period, the cholinergic tone contributes to the levels of circulating GH and, at least until P10, of IGF-1.
ACh affects serum and tissue levels of GHRH, SRIF, and ghrelin in embryos and newborn mice We next investigated whether the developmental deficiency of endogenous ACh in ChAT +/2 mice also affected the main regulators of GH secretion, GHRH, SRIF, and ghrelin. The concentrations of these three hormones were first quantified in the serum of WT and ACh-deficient mice from E18.5 to P21. In mutant embryos, circulating GHRH and ghrelin were markedly lower and, alternativley, SRIF was substantially higher than in WT littermates [ Fig. 5(a) , 5(c), and 5(e)], and, as for GH and IGF-1, these genotype-linked variations were much greater in homozygous than in heterozygous mice. GHRH was more severely affected by the lack of ACh, because its content was reduced by 85% and 95% in heterozygous and in homozygous embryos, respectively, as compared with WT littermates. The cholinergic dependence of these hormones in the serum was maintained postnatally. Whereas GHRH displayed an age-linked increase almost parallel to that of ACh in heterozygous mice [ Fig. 5(b) ], SRIF showed an opposite variation pattern: it remained higher than in WT mice up to P10 and then considerably decreased concomitantly to the increase of ACh until P14 [ Fig. 5(d) ]. As for brain ACh, the serum concentration of each of these hypothalamic hormones became equivalent in ChAT +/2 and WT littermates at P14. Concerning ghrelin, the initially lower postnatal serum content in ChAT +/2 pups became identical to that of WT mice at P10 [ Fig. 5(f) ]. This is mainly due to the gradual decline of ghrelin with age in WT mice and not, as for GHRH, to a marked increase in heterozygous mice. The cholinergic tone thus seems to affect the circulating levels of GHRH and SRIF, and, at least until P10, of ghrelin.
To further check whether the amount of these three hormones in their main tissues of origin is under cholinergic control, we measured the contents of GHRH and SRIF in the hypothalamus and that of ghrelin in the stomach, together with ACh levels, from P7 to P21. The tissue contents of each of these three hormones were clearly dependent on the amount of ACh [ Fig. 6(a), 6 (b), 6(d), 6(f), and 6(g)] and were significantly correlated to it, positively for GHRH and ghrelin [ Fig. 6 (c) and 6(h)] and . ANOVA: no significant effect of genotype (P = 0.3278 for weight and P = 0.1069 for body length) and significant effect of age (P , 0.0001 for both weight and body length); significant age-by-genotype interaction (P , 0.0001 for weight and P = 0.0154 for body length). All pairwise comparisons (ChAT +/2 vs WT at each age) were not significant. Data are presented by sex in Supplemental Tables 4 and 5 and Fig. 1 negatively for SRIF [ Fig. 6(e) ]. Analyses within each age group at P7 and P10 confirmed that these correlations are not a confounding effect of age [Supplemental Fig. 2(b) ; Supplemental Table 8 ]. Noticeably, the age-related changes of these hormones in both tissues paralleled those found in the serum from P7 to P21 [ Fig. 5(b) , 5(d), and 5(f)]. Taken together, these results strongly argue for the cholinergic regulation of GHRH-, SRIF-, and ghrelinproducing cells in the hypothalamus and in the stomach during mouse development.
Discussion
To our knowledge, the present study is the first in vivo demonstration of a relationship between the cholinergic system and the main components of the somatotropic axis during development. The role of ACh was shown in ChAT-knockout (KO) mice, heterozygous mice presenting a new model for transient deficit in endogenous ACh specific to the developmental stage. Although this ACh deficiency did not affect growth or vital functions in newborn mice, it effectively led to the reduction, during the perinatal period, of serum concentrations of GH and IGF-1. The levels of GHRH and SRIF in the hypothalamus and of ghrelin in the stomach were also affected by the loss of ACh, as were GHRH, SRIF, and ghrelin concentrations in the circulation. All of these circulating hormones recovered to normal levels when endogenous ACh contents normalized before weaning.
ChAT-KO mice: a valid model of perinatal ACh deficiency
An extended analysis of the phenotype of the ChAT-KO mice showed prominent characteristics that have not been described for ChAT mutant mice previously obtained by deletion of other exons (44, 45, 48) . We first found that the joints of the vertebral articular processes were fused in ChAT-null embryos. This malformation could be due to the dysfunction of the nonneuronal cholinergic system, whose components (enzymes, transporters, and receptors) are expressed in bone cells and are likely involved in skeletal development (49) . Because movement during embryonic development is crucial for joint formation (50) , the in utero paralysis of the ChAT 2/2 embryos could also be the cause of vertebrae fusion. The second important feature of the ChAT-KO model is that heterozygous mice develop with an approximately twofold deficit in endogenous ACh from the embryonic stage to P10. Afterward, normal ACh levels are spontaneously recovered from the end of the second postnatal week. The requirement for normal amounts of releasable ACh at this developmental stage may be related to the critical role of cholinergic signaling in neuronal differentiation, synapse formation, or myelination processes (51, 52) . A previous study performed in another model of ChAT-KO mice reported the presence of normal levels of ACh in the brain of heterozygous mice at adulthood, explained by the upregulation of the high-affinity choline transporter (CHT) and hence an increase in the supply of choline to ChAT (48) . Our data show that this compensation takes place much earlier and further establish precisely the stage at which it occurs in response to a low rate of ACh synthesis.
A third essential characteristic of the ChAT +/2 mouse model is that, despite reduced levels of ACh, neonates display normal vital physiological functions and growth. The normal postnatal weight gain of ChAT +/2 mice suggests normal food intake throughout preweaning life. In particular, the reduction of ACh synthesis did not seem to affect the functional innervation of the tongue by the cholinergic hypoglossal nerve, required immediately after birth to allow sucking, swallowing, and milk intake. The lack of cardiorespiratory defects was not a priori predictable, because ACh is known to play an important role in the regulation of heart (53) and respiratory (54, 55) activities. The cholinergic control of the respiratory function seems even critical in early life. Indeed, cholinergic dysfunctions have been linked to some cases of sudden infant death syndrome (56, 57) . Mutant mice lacking AChE exhibited increased ventilation and altered responses to hypoxia and hypercapnia within the first few postnatal days (58) . Furthermore, other mutant neonates with severe respiratory defects showed an elevated ChAT expression in parasympathetic neurons and a high pulmonary ACh level (59) . Nevertheless, our results indicate that a twofold decrease of ACh tone during development is not sufficient to affect respiratory and cardiac functions.
Finally, the age-dependent variations in ACh displayed by ChAT +/2 pups occur without the use of any pharmacological agent, and hence turn out to be highly specific and reproducible from mouse to mouse. Moreover, the reduction of ACh synthesis occurs without loss of cholinergic cells. This point is crucial, because the physiological impacts of cholinergic cell removal could not be attributed solely to the disruption of ACh signaling, particularly because other neurotransmitters can be co-released with ACh from the same cholinergic terminal, such as glutamate (60) or g-aminobutyric acid (61) .
Altogether, these data reveal that ChAT +/2 embryos and newborn mice, which present a specific deficit in ACh during the developmental period and are yet functionally normal, provide an animal model particularly convenient to clarify in vivo under physiological conditions the developmental roles of endogenous ACh, in particular on the regulation of the endocrine function.
Also note that in the nervous tissues, the uptake of choline from the extracellular medium driven by CHT has been considered for a long time as the rate-limiting step for ACh synthesis (62) . We previously called this concept into question when we demonstrated that retinoic acid increases ChAT expression, ChAT activity, and ACh contents, whereas it concomitantly inhibits CHT expression and choline uptake activity in cultured sympathetic neurons of newborn rats (63, 64) . In this study, we clearly show that the reduction of ChAT gene expression in developing ChAT +/2 mice results in the decrease of endogenous ACh levels, both in the central nervous system and at the periphery. These findings support the notion that ChAT is a key component of the rate-controlling process for ACh synthesis in vivo, at least during development. A tight control of ChAT expression is thus essential to regulate ACh levels, and thus the cholinergic function, in the nervous system.
ACh actions on the main components of the somatotropic axis during development
We have shown in the present study that, at both embryonic and postnatal stages, endogenous ACh modulates Figure 5 . ACh impacts the levels of circulating GHRH, SRIF, and ghrelin during development. Serum levels of (a and b) GHRH, (c and d) SRIF, and (e and f) ghrelin measured in (a, c, and e) E18.5 embryos and (b, d, and f) pups from 2 to 21 days of age are shown. Data are means 6 standard error of the mean [GHRH: (a) n = 3 to 5, (b) n = 3 to 7); SRIF: (c) n = 5 to 10, (d) n = 5 to 10); ghrelin: (e) n = 6 to 10, (f) n = 5 to 10). ANOVA: (a, c, and e), significant effect of genotype (P , 0.0001 in each case); (b, d, and f), significant effect of genotype and age (genotype, P , 0.0001 in each case; age, P = 0.0394 for GHRH and P , 0.0001 for SRIF and ghrelin); significant age-by-genotype interactions for each hormone (P , 0.0001 in each case). *P , 0.05, ***P , 0.001 [ChAT the levels of GH and IGF-1 in the bloodstream. Serum GH was positively correlated to brain ACh, which highlights the strong relationship between the cholinergic tone and circulating GH. However, the variation profiles of serum IGF-1 were quite different from those of serum GH. Most particularly, an age-dependent decrease of serum IGF-1 was observed in WT animals, which apparently occurs independently of our GH measurements and of course of ACh.
In the mouse, as in other mammals, GH release is characterized by peak secretion periods flanked by interpulse periods of stable baseline secretion. The measurements of circulating GH performed in this study likely reflect basal secretion. In support to this possibility, all serum GH concentrations measured at each age were homogeneous and consistent with basal interpulse levels of GH reported for the blood of adult WT mice (65, 66) . The pattern of GH pulsatility has a crucial impact on its downstream actions, particularly in the liver. Actually, intermittent GH delivery to hypophysectomized rats is much more effective than continuous GH infusion at stimulating hepatic IGF-1 production (67). This strongly suggests that pulsatile GH signals are more critical than basal GH release to stimulate the production of liverderived IGF-1, which is the major source of IGF-1 in the Figure 6 . ACh affects the levels of GHRH and SRIF in the hypothalamus and of ghrelin in the stomach during postnatal development. Levels of (a) ACh, (b) GHRH, and (d) SRIF were measured in the hypothalamus, and those of (f) ACh and (g) ghrelin in the stomach of WT and ChAT +/2 littermates from P7 to P21. Values are means 6 standard error of the mean (n = 4 to 8 in the hypothalamus; n = 5 to 7 in the stomach). ANOVA: significant effect of genotype and age for ACh (a and f) and each hormone in the hypothalamus (b and d) and the stomach (g) [genotype: P , 0.0001 for SRIF, ghrelin, and ACh in both tissues, P = 0.0009 for GHRH; age: P , 0.0001 for SRIF, ghrelin, and ACh in both tissues, P = 0.001 for GHRH]; age-by-genotype interactions significant for ACh in the hypothalamus (P = 0.0004), for GHRH, SRIF, and ghrelin (P , 0.0001 in each case), not significant for ACh in the stomach (P = 0.1932). Data are presented by sex in Supplemental Table 3 Table 8 , and Supplemental Fig. 2(b) for complementary statistical analyses. *P , 0.05, **P , 0.01, ***P , 0.001 (ChAT +/2 vs age-matched WT mice).
doi: 10.1210/en.2017-03175 https://academic.oup.com/endoblood (68, 69) . Taken together, these results may explain the divergence between the age-related variations of GH and IGF-1 in the circulation observed in WT mice. Moreover, they suggest that the postnatal decline in IGF-1, at least at the latest stages of development investigated in this study, could reflect age-dependent changes in GH patterning. Experimental limitations prevented us from exploring this issue (see later). The phenotypic exploration of ChAT +/2 mice revealed that the developmental deficit in circulating GH and IGF-1 had no noticeable consequence to body weight or length. Given the prominent roles of GH and IGF-1 in growth (7), this result may somewhat be puzzling. Actually, the normal weights and lengths of ChAT +/2 embryos at E18.5 may be accounted for by the fact that fetal pituitary GH does not seem to be essential for normal intrauterine growth, which is mainly controlled by placental hormones (70) . In line with this, mouse mutant strains, such as Snell and Ames dwarf mice, in which pituitary GH synthesis is undetectable from birth to adulthood, display normal lengths at birth, and growth retardation in these mice does not manifest itself before 2 weeks of age (71) . Growth in mice during the early postnatal period thus does not seem to require high levels of endogenous GH. This is confirmed in other GH-deficient strains, in which growth failure is not significant before the third or fourth week of age [GHRH-KO mice (72), Br-M3-KO mice (25) ]. In ChAT +/2 mice, the GH deficit is transient and normal GH levels are already restored at 2 weeks of age, which may explain why they do not exhibit any postnatal growth retardation. This transient GH deficit also seems to have no long-term impact on weight in adult mice. Moreover, the 50% reduction in serum IGF-1 in ChAT +/2 mice at early stages shows no effect on growth. This is consistent with the observation that following the liver-specific deletion of the igf1 gene, mouse postnatal growth is not affected by a 75% reduction in serum IGF-1 levels, suggesting that the local production of IGF-1 is more important for mouse growth than circulating IGF-1 (68) . IGF-1 is produced in many tissues, and skeletal muscle IGF-1, through local autocrine and/or paracrine actions, seems essential for mouse postnatal growth (73) . Therefore, the regulation of muscle-specific IGF-1 synthesis may contribute to the maintenance of normal growth in ChAT +/2 mice. This issue needs to be explored in future investigations.
We found in the present study that the disruption of cholinergic tone also contributed to the alteration of the levels of GHRH, SRIF, and ghrelin in the circulation. Although the main source of GHRH and SRIF is the hypothalamus and that of ghrelin is the stomach, these hormones can also be produced in other tissues (19, 74, 75) . Therefore, their serum concentrations may not reflect the amount produced by hypothalamus and stomach.
In both tissues, we found that the amount of each hormone is directly correlated to ACh levels between P7 and P21. These results indicate that in the developing mice, ACh acts as a positive or a negative signal on cells that synthesize GHRH and SRIF in the hypothalamus and ghrelin in the stomach. In line with this, in adults, cholinergic fibers are distributed throughout the hypothalamus, particularly in the arcuate and periventricular nuclei (76) and cholinergic receptors are expressed in several hypothalamic areas, including these two nuclei, notably by most of the GHRH-producing neurons (25) . The gastric mucosa also contains a prominent network of cholinergic fibers of extrinsic (vagal innervation) and intrinsic (myenteric neurons) origin (77) . However, this does not exclude a possible direct action of ACh on the developing pituitary to control the activity of somatotrophs. In support to this possibility, exogenous ACh has been shown to stimulate GH secretion by ex vivo pituitaries of neonatal rats (78) and the anterior pituitary of rodents has cholinergic receptors, at least at adulthood (79) . Because, to our knowledge, these receptors have been reported on pituitary cells other than the somatotroph cells (80), ACh may not provide a direct input to GH-producing cells.
We observed that, from P7 to P21, the ACh-linked variations in the levels of GHRH and SRIF in the hypothalamus and of ghrelin in the stomach were closely related to changes in their serum concentrations. This suggests that the cholinergic tone affects the levels of these hormones in the circulation and may modulate their synthesis and not just their secretion. However, our one-off measurements of these hormones in the circulation may not reflect the amount of GHRH and SRIF secreted into the hypothalamo-hypophyseal portal vasculature, and thus their action as mediators of ACh action on the regulation of GH secretion from the pituitary gland. Quantifying the levels of these hormones in the portal circulation is required to validate or reject this hypothesis. Collecting blood samples from hypophyseal portal vessels to evaluate GHRH and SRIF release into portal blood has been previously reported in sheep (20) . However, it is unlikely to be feasible in rodents, especially in newborn mice. Nevertheless, in adult sheep, the administration of an AChE inhibitor induces a marked increase in GHRH release into the portal blood, related to a rise in GH in the systemic blood (20) . This suggests, at least in this species, that the stimulation of GH release by the cholinergic system is mediated partly by modifications in the activity of GHRH neurons and in GHRH secretion.
The presence of GH, IGF-1, GHRH, SRIF, and ghrelin in the adult blood flow raises questions about their origin in the embryonic serum. Are they produced by the embryo or are they provided by the maternal circulation?
The transplacental passage of pituitary GH or IGF-1 from the maternal circulation is thought to be negligible (81, 82) . In contrast, exogenously administered SRIF or ghrelin into pregnant dams is transferred to the fetal circulatory system (83, 84) , indicating that both peptides of maternal origin can cross the placental barrier. Nonetheless, all the embryos used in this study originated from dams with the heterozygous genotype, and the serum content of each hormone at a given age varied only according to the genotype of the embryo itself. Furthermore, the genotype-dependent differences in serum hormone concentrations were always salient in embryos from the same litter and were reproducible from litter to litter. Thus, all the hormones measured in the embryonic serum do not seem to predominantly derive from the maternal circulation. Finally, because these hormones display a short half-life in adulthood (,30 minutes), those that have been quantified in the serum of newborn mice are unlikely to be of maternal origin but are produced by the pups themselves.
This study highlights that the developing endocrine system is particularly vulnerable to the disruption of cholinergic transmission. Consequently, substances that modify ACh levels may affect hormonal production in the developing organism. Among these chemicals, organophosphorus compounds (OP), which include the most used pesticides worldwide and potent warfare nerve agents, all disrupt the cholinergic transmission by inhibiting AChE and thus prolonging the action of ACh. The resulting central and peripheral cholinergic hyperstimulation leads to adverse health effects (85) . It is well recognized that developing organisms are more susceptible than mature organisms to the neurotoxic effects of OP, probably due to their lower metabolic abilities. Both acute exposure to OP or prolonged exposure to low levels of environmental OP interfere with neurodevelopmental processes, so that animal models or humans exposed in utero (OP cross the placental barrier) or as juveniles exhibit endocrine abnormalities (86) , mainly reported at prepubertal/postpubertal and adult stages, as well as motor (87) and cognitive (88, 89) delays. To our knowledge, the immediate impact of OP exposure on the endocrine function of developing individuals lacks documentation. The present study, showing that the alteration of the cholinergic tone impairs the function of the endocrine system in the embryo and neonates themselves, strongly suggests that the exposure to OP in early life may have profound and immediate effects on the endocrine function.
Limitations
The present study was focused on analyzing the consequences of the disruption of ACh synthesis in terms of the major components of the GH axis during development, and was thus mainly centered on the developmental period from E18.5 to P21. We showed that the developmental ACh depletion displayed by ChAT +/2 mice had no apparent impact on pup growth and on weight in adulthood, most probably because this deficit is transient. Additional studies are thus needed to support the view that ACh is an essential regulator of the GH/IGF-1 axis. To do so, the physiological impact of early-life ACh deficits on GH axis function in adult mice, in particular on GH secretory patterning and on GHRH and SRIF neuron activity, should be explored. However, because ACh levels return to normal from P14 in ChAT +/2 mice, this model may not be the most appropriate to assess the role of ACh on GH axis function in adulthood. The depletion of endogenous ACh after P14 should allow this limitation to be circumvented. The selective inactivation of cholinergic neurotransmission at the level of the hypothalamus could be performed by silencing ChAT gene expression via the stereotaxic administration of either a viral vector expressing a ChAT-specific shRNA (90) in WT or ChAT +/2 mice, or a Cre recombinase-expressing viral vector in ChAT floxed mice (37) .
As mentioned previously, the measurements reported in the present study likely reflect basal GH secretion. Therefore, our data are not very informative as to the potential contribution of ACh to the regulation of the GH secretion patterning. Establishing the pulsatile GH profile requires the collection of sequential blood samples from the same animals, which is extremely challenging at early stages of the postnatal period, mainly because of limited blood volume. Again, because ACh levels in ChAT +/2 mice are normalized from P14, GH patterning in the presence of low levels of ACh cannot be assessed in this mouse model at later stages at which blood volume is no longer limiting (beyond P21). Nevertheless, the potential long-term impact of altered developmental ACh on the perturbation of the GH secretory pattern is worth investigating in these mice in future studies.
The morphology of the pituitary gland of ChAT +/2 mice has not been explored in this study. Pronounced pituitary hypoplasia associated with drastic GH deficits has been reported in adulthood in several mutant strains, such as Snell and Ames dwarf mice (71), GHRH-KO mice (72) , and Br-M3-KO mice (25) . However, pituitary size appears normal in Br-M3-KO neonates (25) , suggesting that, as for growth retardation, pituitary alteration does not occur during the first 2 postnatal weeks in GHdeficient mice. In ChAT +/2 mice, normal concentrations of circulating GH are maintained from from P14 to adulthood (not shown), suggesting that somatotroph cells function normally during this period. It thus seems unlikely that pituitary gland morphology and function are impaired in ChAT +/2 mice, at least from P14.
Nevertheless, such pituitary alterations may occur transiently before this age in these mice. The pituitaries of WT and ChAT +/2 mice at early postnatal stages deserve examination to evaluate their size, particularly with regard to the anterior lobe, as well as the number of somatotroph cells.
Conclusion
This study provides evidence that ChAT +/2 mice display an unexpected developmental deficit in endogenous ACh until the end of the second postnatal week, and represents a unique model to address the role of the cholinergic system during development and under physiological conditions. The phenotypic exploration of ChAT mutant mice has emphasized the developmental role of ACh as a potential modulator of the main components of the somatotropic axis. This new result completes the range of functions known to be orchestrated by the cholinergic system. It would additionally be interesting to examine whether the hormones of the somatotropic axis are also impaired in other mouse models of genetic disruption of the cholinergic transmission at presynaptic level obtained by targeting the CHT gene (91) or the gene encoding the vesicular ACh transporter (92, 93) . Whether ACh developmental action can be expanded to the regulation of other neuroendocrine systems remains to be determined, in particular those controlled by the hypothalamus. Ongoing studies should also further clarify whether the developmental defects in ACh in such a model have a lifelong impact on metabolic regulation or behavior.
